Premium
Cancer Therapy: Diamond‐Lipid Hybrids Enhance Chemotherapeutic Tolerance and Mediate Tumor Regression (Adv. Mater. 26/2013)
Author(s) -
Moore Laura,
Chow Edward KaiHua,
Osawa Eiji,
Bishop J. Michael,
Ho Dean
Publication year - 2013
Publication title -
advanced materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.707
H-Index - 527
eISSN - 1521-4095
pISSN - 0935-9648
DOI - 10.1002/adma.201370168
Subject(s) - nanodiamond , materials science , cancer , in vivo , drug delivery , cancer research , pharmacology , biocompatibility , drug , oncology , biomedical engineering , nanotechnology , medicine , diamond , biology , microbiology and biotechnology , composite material , metallurgy
To facilitate targeted drug delivery using nanodiamond (ND) vehicles, epirubicin‐functionalized ND/lipid hybrids are coupled to epidermal growth factor receptor (EGFR) antibodies. The resulting particles mediate tumor regression, and markedly improve drug tolerance in a triplenegative breast cancer model in vivo. Furthermore, comprehensive biocompatibility analysis following intravenous ND administration indicate that the particles are well tolerated by mice. Further information can be found in the article by Dean Ho and co‐workers on page 3532 .